1781223-80-0
1781223-80-0 structure
- Name: Telisotuzumab
- Chemical Name: Telisotuzumab
- CAS Number: 1781223-80-0
- Molecular Formula:
- Molecular Weight:
- Catalog: Research Areas Cancer
- Create Date: 2023-01-28 17:25:49
- Modify Date: 2025-08-25 11:54:26
-
Telisotuzumab (ABT-700) is a human recombinant bivalent antibody, a therapeutic antibody against the hepatocyte growth factor receptor (MET) that binds c-Met with high affinity and inhibits c-Met signaling. Telisotuzumab has antitumor activity[1].
| Name | Telisotuzumab |
|---|
| Description | Telisotuzumab (ABT-700) is a human recombinant bivalent antibody, a therapeutic antibody against the hepatocyte growth factor receptor (MET) that binds c-Met with high affinity and inhibits c-Met signaling. Telisotuzumab has antitumor activity[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Telisotuzumab (ABT-700) (10 μg/mL, 24 h) 可以抑制 SNU5 细胞的增殖，并导致促凋亡的 Bim 增加和抗凋亡的 Bcl-xL 减少，从而诱发细胞凋亡[1]。 |
| In Vivo | Telisotuzumab (ABT-700) (i.p., 2.5-40 mg/kg, twice a week, 90 days) 有效拮抗构成性激活的 c-Met 和下游信号，从而抑制 Hs746T 细胞 SCID 小鼠的肿瘤生长[1]。 Animal Model: SCID mice with Hs746T cells[1] Dosage: 2.5-40 mg/kg Administration: i.p., twice a week, 90 days Result: Reduced total and phosphorylated c-Met as well as phosphorylated Akt and Erk. Complete tumor regression at doses above 10 mg/kg but no effective inhibition of tumor growth at doses below 5mg/kg. |
| References |
| No Any Chemical & Physical Properties |